- Home
- PKBK vs DCTH Comparison
PKBK vs DCTH Comparison
Compare PKBK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PKBK | DCTH |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.7M | 311.7M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PKBK | DCTH |
|---|---|---|
| Price | $30.17 | $10.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 103.1K | ★ 270.4K |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | 39.21 | ★ 107.53 |
| EPS | ★ 3.16 | 0.07 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ $9.50 | $155.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.52 | $8.12 |
| 52 Week High | $31.45 | $18.23 |
Technical Indicators
Market Signals| Indicator | PKBK | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 61.27 |
| Support Level | $26.56 | $10.50 |
| Resistance Level | $31.45 | $11.25 |
| Average True Range (ATR) | 0.65 | 0.37 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 47.78 | 76.16 |
Price Performance
Historical ComparisonAbout PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.